The standout: teplizumab is the first drug that actually changes the T1D trajectory — a median two-to-three-year delay in clinical onset, from one well-run trial. The screening side does almost as much work on its own: kids whose autoantibody status is known almost never present in DKA, the dangerous crisis that lands one in four undiagnosed kids in intensive care. The catch: the drug runs about $194,000 a course before insurance, and a positive screen brings family anxiety before relief. For first-degree relatives of someone with T1D, the screening is free and trivially low-burden — that part is close to a no-brainer; the treatment decision is the harder one.
T1D is an autoimmune disease. Specific T cells decide that the insulin-producing beta cells in the pancreas are foreign and kill them off over months to years. By the time a child is suddenly thirsty, peeing constantly, and losing weight — the classic textbook diagnosis — roughly 80 to 90% of the beta cells are already gone. But the immune attack starts much earlier, and it leaves a trace in the blood: islet autoantibodies. Two or more of them, persistent in childhood, mean the attack has started. From that moment, clinical diabetes is essentially inevitable — 84% of multi-antibody-positive children progress within fifteen years, and lifetime risk approaches a hundred percent Ziegler et al. 2013. The clock is what's variable, not the destination.
Teplizumab targets the T cells doing the killing. It's an antibody that grabs onto CD3 — a docking point that every T cell carries on its surface — and partially deactivates it. The autoreactive cells get pushed into a worn-out, anergic state; regulatory cells that calm autoimmunity expand at the same time. The drug doesn't reverse the attack. It pauses it. Beta cells get a stay of execution, and the slow drift to symptomatic diabetes slows down with them.
Screening works the other end of the same biology. A single blood draw checks for four islet autoantibodies (against GAD65, IA-2, ZnT8, and insulin). Two or more on a confirmatory test, paired with an oral glucose tolerance test, places a child in one of three stages: Stage 1 (antibodies, normal glucose), Stage 2 (antibodies, glucose readings that are no longer normal but not yet diabetic), or Stage 3 (clinical diabetes). Stage 2 is teplizumab's approved window. The staging framework was formalized by JDRF, the Endocrine Society, and the ADA in 2015 and is now the standard reference Insel et al. 2015.
What the trial actually showed
The pivotal trial is small but clean. Seventy-six relatives of T1D patients, all in Stage 2, randomized double-blind to a single 14-day course of teplizumab or placebo. The result: median time to clinical diabetes was 48.4 months on the drug versus 24.4 months on placebo. A roughly two-year delay in a population whose progression to insulin dependence was otherwise a near-certainty within five years.
A second phase-3 trial, PROTECT, tested teplizumab in children and teenagers already diagnosed with new-onset T1D, within six weeks of diagnosis. Three hundred and twenty-eight kids randomized two-to-one; the treated group held onto their remaining insulin-making capacity (measured by C-peptide) significantly better than the placebo group at eighteen months. PROTECT didn't change the FDA label — teplizumab remains approved only for the Stage 2 delay — but it independently confirms that the drug does what it's supposed to do to the immune system Ramos et al. 2023.
The screening evidence sits on a different shelf — large, slow, observational, decades old. Cohorts like TEDDY, DAISY, and BABYDIAB have tracked thousands of genetically at-risk children for twenty-plus years, and their pooled finding is the foundation of the staging framework: persistent multi-antibody positivity in childhood means clinical T1D almost certainly arrives Ziegler et al. 2013. The Fr1da program in Bavaria pushed this from "we know the natural history" to "we can find these kids in a regular pediatric office" — screening about 90,000 children aged 2 to 5 and finding Stage 1 or 2 in roughly 0.3% Ziegler et al. 2020.
The unscreened pathway
Picture the version of T1D nobody screens for. Your kid says they're thirsty in the morning. They're still thirsty in the afternoon. They're up all night drinking water and using the bathroom. Then they're vomiting. Then they're confused, breathing strangely, abdominal pain getting worse. The ER, the diagnosis, the ICU. About one in four American children diagnosed with T1D arrive at the diagnosis this way — in DKA, a metabolic emergency that's measurably damaging to the developing brain and occasionally fatal. The diagnosis would have happened anyway. You're now learning insulin dosing while your child is in critical care.
Stretch the timeline out a decade. Every year T1D runs unchecked is a year of higher average glucose, and every year of higher average glucose compounds the small-vessel damage that becomes retinopathy, kidney disease, and cardiovascular risk in the third and fourth decades of life. Two or three years of normal pancreatic function in childhood isn't symbolic. It's two or three years of not finger-sticking, not pump-troubleshooting, not 3 AM low-glucose alarms — and two or three fewer years on the cumulative damage clock.
For families with one child already diagnosed, the unspoken question about a younger sibling — or the cousin who looks tired this week — doesn't go away. Screening doesn't make the next diagnosis less likely. It makes you ready for it.
How to actually do it
For relatives of a T1D patient — first-degree or second-degree, ages 2.5 to 45 — screening is free through TrialNet's Pathway to Prevention program. You request a kit on the TrialNet website; it arrives in the mail; you do a finger-prick at home (kids) or a venous draw at a participating site; results come back in four to six weeks. A negative test for someone under 18 gets re-checked every year. A positive test triggers a confirmatory venous draw and an oral glucose tolerance test, which together establish the stage.
The teplizumab course is fourteen consecutive weekdays at a specialty infusion center, usually a hospital-based pediatric endocrinology unit. Each visit runs about 1.5 to 2.5 hours — premedication, the infusion itself, observation. The dose ramps over days 1 to 5 (a small starting dose to let the body get used to it), then holds at the full 1,030 μg/m² dose through day 14. Baseline labs first: a complete blood count, liver enzymes, EBV and CMV serology, a pregnancy test, vaccine status. Lymphocyte counts are checked at intervals over the next six months while they recover FDA 2022.
When not to do this
Teplizumab is a real immunosuppressant. The screen for who shouldn't receive it is part of how the course gets safely delivered — the infusion center checks every item at the baseline visit, and a positive flag postpones or cancels treatment.
Screening itself has no medical contraindication — a blood draw is a blood draw — but families weighing whether to screen a young child wrestle with a different concern: living with an answer they can't yet act on, especially if the child is younger than the FDA's 8-year cutoff for teplizumab. That's a judgment about timing, not a medical contraindication. The DKA-avoidance benefit applies at any age; the drug option just isn't on the table until 8.
Three things to unlearn
"Teplizumab cures T1D." It doesn't. It delays clinical onset by a median of two to three years. On long-term follow-up, the curves between treated and placebo participants keep converging — most treated patients eventually develop clinical diabetes anyway Sims et al. 2021. Delay matters. Delay is not the same word as prevent.
"T1D runs in families, so screening is for families with a history." Only about 10 to 15% of new T1D cases happen in someone with a first-degree relative who already has it. The other 85 to 90% appear with no family warning. Family-based screening is high-yield for relatives, but most of the future T1D population lives in families with no history — which is why general-population pilots like Fr1da in Germany and ASK in Colorado exist Ziegler et al. 2020.
"Better not to know." The unscreened pathway leads to DKA at diagnosis in about a quarter of US pediatric cases. The screened pathway — even without teplizumab, just with monitoring — drops that to roughly one in twenty Hummel et al. 2023. "Not knowing" doesn't postpone the disease. It postpones the preparation.
Who this is for
First- and second-degree relatives of a T1D patient. The screening is free, mailed to your house, takes a finger-stick. Of relatives screened, roughly 3 to 5% test positive for two or more autoantibodies — much higher than the general-population rate. If you have a sibling, parent, child, aunt, uncle, or cousin with T1D, this is the highest-yield use of the program and the clearest case for opting in.
Children with no family history. The math is harder. Yield in general-population pediatric screening runs roughly 0.3 to 0.5% — meaning a few hundred negative screens for each positive one. General-population programs (Fr1da in Germany, ASK in Colorado) make this work through pediatrician-office partnership; outside research catchments it's hard to access. The ADA's 2024 Standards of Care recommend high-risk relative screening and note that broader pediatric screening is reasonable where the infrastructure exists ADA 2024.
Children under 8. Screening still works — and the DKA-avoidance benefit applies the day the result comes back — but teplizumab itself isn't FDA-approved below age 8. For a 4-year-old with two autoantibodies, monitoring is the action; the drug option opens up when they reach the cutoff and remain Stage 2.
Adults with no family history but a suspected slow-onset autoimmune diabetes (LADA). The screening-and-prevention paradigm is less developed here; teplizumab isn't approved for this population. Worth a conversation with an endocrinologist, but it's not the same well-evidenced pathway.
If teplizumab is off the table
For Stage 2 patients, the realistic alternative is watchful waiting — every-6-month OGTT and HbA1c monitoring through TrialNet or a pediatric endocrinologist, with prompt clinical care when Stage 3 arrives. This is the right call when teplizumab is unavailable, declined, or financially out of reach. It preserves the central DKA-avoidance benefit of screening without taking on the drug's cost or infusion burden. What you give up: the median two-to-three-year delay.
Other immunomodulators have been tried in T1D — abatacept, anti-thymocyte globulin, rituximab, oral and nasal insulin, verapamil. None has shown the delay effect that teplizumab did at Stage 2. Verapamil has small trials in new-onset T1D suggesting modest preservation of insulin-making capacity, but no Stage 2 prevention data. As of 2024, teplizumab is the only FDA-approved drug for delaying clinical T1D onset.
Where this breaks down in practice
Screening declined because the benefit feels abstract. When the value proposition is framed as "learn your child's odds of a future disease," families often opt out. When it's framed as "avoid the ICU diagnosis and gain treatment options," uptake climbs. The framing matters as much as the science.
Lost to follow-up after a positive screen. The lag between Stage 2 and Stage 3 is long enough that families drift. Missing the 6-monthly monitoring visits means missing the moment Stage 2 actually arrives — which means missing both the narrow teplizumab window and the DKA-prevention benefit at the same time. A reliable pediatric endocrinologist who runs the recall system is half the value.
Insurance denial during the eligibility window. Early post-approval data show prior-authorization denials in roughly a quarter of cases — typically overturned on appeal, but the appeal eats weeks. Endocrinologists experienced with teplizumab handle this efficiently; first-time prescribers often don't. Worth asking the prescribing team how many courses they've put through and how long their average authorization takes.
Expecting a second course. The FDA label permits one course only. Families hoping to re-treat after the delay runs out have nowhere to go yet; re-treatment trials are still pending.
Infection in the post-infusion months. Lymphocyte counts drop 60 to 80% during the course and recover over two to six months. Most patients sail through; the rare bad outcomes happen when post-treatment monitoring of blood counts, liver enzymes, and viral serology gets skipped during the recovery window.
Cost, access, logistics
Cost. Screening through TrialNet is free. Teplizumab's list price is about $194,000 for the 14-day course — Sanofi's (formerly Provention Bio's) price set at launch ICER 2023. Most US insurers — Medicare, most commercial plans, most state Medicaid programs — cover teplizumab with prior authorization when Stage 2 criteria are met. Out-of-pocket varies from $0 (full Medicaid, low-deductible commercial) to several thousand on high-deductible plans; the manufacturer's patient-assistance program covers some uninsured and underinsured patients.
Where to access screening. TrialNet's Pathway to Prevention covers the US, Canada, Australia, the UK, several European countries, and Israel — eligibility is having a relative with T1D. For US children without a family history, ASK (Autoimmunity Screening for Kids, run out of Colorado) is the main general-population option; Fr1da operates the same model in Bavaria. Outside these programs, screening usually requires a pediatric endocrinology referral and a paid lab order — running on the order of $50 to $200 McQueen et al. 2020.
Where to access teplizumab. Specialty infusion centers, usually hospital-based pediatric endocrinology units. The 14 consecutive weekdays mean two weeks of school or work disruption — many families schedule the course over a summer or winter break when possible. Lab orders, prior authorization, and infusion scheduling are coordinated by the prescribing endocrinology team.
Outside the US. NICE (UK), the EMA, and other national bodies are still evaluating teplizumab's cost-effectiveness as of 2024; access varies country by country. The screening side is broadly available worldwide; the drug side is patchy.
What changes when you screen
In the first weeks after a positive screen, the news lands hard. A child who looked healthy yesterday now has a label, a clinic schedule, and an expected disease in the future. Both the Fr1da team and the TEDDY cohort have measured this — parental distress rises, then adapts over months, and a year out it's typically lower than the background worry families carried when they didn't know Hummel et al. 2017 Johnson et al. 2011. The unknown was worse than the known.
A year in, what people around the family notice is unremarkable. The child plays soccer, goes to school, eats birthday cake, sees the endocrinologist twice a year. The OGTT becomes routine. The household runs glucose-aware — pediatrician knows, school nurse knows, the older sibling knows — but daily life looks like every other family's.
If teplizumab is on the table and the family chooses it, the two-week course is the visible event: school accommodations, daily trips to the infusion center, a tired kid in the first few days from the immune reaction, settling out by week two. Three months in, lymphocytes are recovering. Six months in, the OGTT looks the same as it did before treatment. A year in, it's still holding. Eighteen months in, where placebo participants from the trial were starting to tip into clinical diabetes, this child is still Stage 2 Herold et al. 2019.
The Stage 3 transition, when it comes, comes through the clinic, not the ER. The family has the supplies, the endocrinologist on speed dial, the school 504 plan, and the insulin protocol already known. A diagnosis that would otherwise have been a crisis becomes a calendar appointment Hummel et al. 2023.
For families who screen and learn they're negative: the gradual fade of the background worry over a sibling, a cousin, a niece. Negative under-18s re-screen yearly, which keeps the answer current rather than settling it once and forgetting.
Adjacent topics worth knowing about: continuous glucose monitoring and closed-loop insulin systems (the standard-of-care frame for established T1D); beta-cell replacement therapies — islet transplantation and the newer stem-cell-derived approaches — which are early but moving fast; type 2 diabetes prevention (different pathophysiology, different toolkit); and the T1D genetic risk scores (T1D-GRS2) that may eventually be used to enrich who gets screened.
- — Type 1 diabetes and celiac cluster in the same families. A celiac diagnosis is a nudge to know your own T1D risk.
- — Once T1D risk is known, a glucose monitor is how families catch the rise before it becomes a crisis.
- — Screening relatives for type 1 diabetes is family risk testing in spirit: antibodies and genes flag who to watch years early.
- — This is type 1 — an autoimmune attack you can screen for and delay — not type 2, a different disease with a different playbook.
Substance + claimed effects
Teplizumab (Tzield) is a humanized anti-CD3 monoclonal antibody, FDA-approved on 17 November 2022 as the first disease-modifying therapy for type 1 diabetes — specifically, to delay onset of Stage 3 (clinical) T1D in patients ≥8 years old with Stage 2 T1D (multiple islet autoantibodies plus dysglycemia) FDA 2022. The substance comprises two tightly coupled components: (1) the drug itself, delivered as a single 14-day course of daily IV infusions, and (2) the autoantibody screening apparatus that identifies eligible candidates — primarily relatives of T1D patients (via TrialNet's Pathway to Prevention) and general-population pediatric programs (Fr1da in Bavaria, ASK in Colorado). Claimed effects span: median delay of ~2–3 years in time to clinical T1D diagnosis among Stage 2 individuals Herold et al. 2019 Sims et al. 2021; preservation of C-peptide and β-cell function when given at new-onset Stage 3 Ramos et al. 2023; ~80–95% reduction in diabetic ketoacidosis (DKA) at clinical diagnosis through monitored screening pathways Hummel et al. 2023; longevity benefit through reduced cumulative hyperglycemia exposure; modest mood / family-anxiety effects from knowing autoantibody status; and a substantial cost burden ($193,900 US list price per course) ICER 2023. The entry treats screening + drug as one decision pathway because they only make sense together: the drug requires the screen, and the screen is what makes the drug actionable.
Evidence by addressing question
mechanism
T1D is a T-cell-mediated autoimmune destruction of pancreatic β-cells. CD8+ effector T cells, with help from CD4+ Th1 cells, recognize islet antigens (insulin, GAD65, IA-2, ZnT8) and progressively kill insulin-producing β-cells over months to years. By the time symptomatic hyperglycemia appears, ~80–90% of β-cell mass is gone — but seroconversion to multiple islet autoantibodies precedes Stage 3 by a median of several years and identifies the disease before symptoms Insel et al. 2015.
Teplizumab is a Fc-modified anti-CD3ε monoclonal antibody. It binds the CD3 epsilon chain of the T-cell receptor complex, partially down-modulating TCR signaling rather than depleting T cells outright. The dominant mechanistic effects: (1) induction of a partially exhausted/anergic phenotype in autoreactive effector T cells, with upregulation of inhibitory receptors (PD-1, TIGIT, KLRG1); (2) preferential expansion of CD8+ regulatory-like and central-memory T cells; (3) transient peripheral lymphopenia that recovers over 2–6 months. The Fc modification minimizes cytokine release relative to first-generation anti-CD3 antibodies. Mechanistically, the drug doesn't reverse autoimmunity — it pauses progression by remodeling the effector T-cell compartment, buying β-cells time Herold et al. 2019 Sims et al. 2021.
Screening mechanism: serum (or capillary) detection of ≥2 of four islet autoantibodies — GAD65, IA-2, ZnT8, mIAA (micro-insulin autoantibody) — establishes Stage 1 (normoglycemia) or Stage 2 (with dysglycemia: impaired fasting glucose, IGT on OGTT, or HbA1c rise). The staging framework was formalized by JDRF/ADA/Endocrine Society in 2015 and adopted by ISPAD in 2022 Insel et al. 2015 Besser et al. 2022.
evidence
The pivotal prevention trial — TN-10, conducted by TrialNet — randomized 76 relatives of T1D patients (median age 14, range 8–49) with Stage 2 T1D to a single 14-day course of teplizumab (n=44) or placebo (n=32). Median time to clinical T1D was 48.4 months in the teplizumab group versus 24.4 months in placebo — a 24-month median delay; hazard ratio 0.41 (95% CI 0.22–0.78, p=0.006) Herold et al. 2019. Extended follow-up at a median 923 days showed the delay had widened: median time-to-diagnosis 59.6 months (teplizumab) vs 27.1 months (placebo), a ~32.5-month delay; 50% of teplizumab recipients remained diabetes-free at follow-up versus 22% of placebo Sims et al. 2021. C-peptide responses, a measure of preserved β-cell function, were higher in treated participants.
The PROTECT phase-3 trial (n=328, ages 8–17, randomized 2:1) tested teplizumab in new-onset Stage 3 T1D, given within 6 weeks of diagnosis. At 78 weeks, stimulated C-peptide AUC was significantly higher in the teplizumab arm (difference 0.13 pmol/mL, p<0.001), indicating slowed β-cell decline. HbA1c, insulin use, and time-in-range did not differ significantly — the trial demonstrated β-cell preservation but not, in this short follow-up, downstream glycemic benefit Ramos et al. 2023. PROTECT extends the case for teplizumab beyond pure prevention but the FDA label remains restricted to Stage 2 delay; off-label use at new-onset is plausible but not approved.
Screening evidence: TEDDY, DAISY, BABYDIAB, and DiPiS — long-running natural-history cohorts of genetically at-risk children — established that progression to clinical T1D in those with ≥2 persistent islet autoantibodies is ~44% at 5 years, ~70% at 10 years, ~84% at 15 years; lifetime risk approaches 100% Ziegler et al. 2013. The Fr1da study screened ~90,000 Bavarian children aged 2–5 years; yield of presymptomatic Stage 1/2 T1D was 0.31% (280 children), with high family acceptance and a DKA rate at eventual clinical diagnosis of ~5% versus 20–30% in unscreened pediatric populations Ziegler et al. 2020 Hummel et al. 2023. TrialNet's Pathway to Prevention has screened >250,000 first- and second-degree relatives of T1D patients in the US, Australia, and Europe since 2004, with autoantibody yield ~3–5% in first-degree relatives.
protocol
Screening protocol: TrialNet (trialnet.org) offers free at-home or in-lab autoantibody testing (single capillary or venous blood draw, 4-antibody panel) for anyone with a first- or second-degree T1D relative aged 2.5–45. Initial positive screen triggers confirmatory venous test and oral glucose tolerance test (OGTT) for staging. Negative children under 18 are re-tested annually; positive participants enter 6-monthly metabolic monitoring (OGTT, HbA1c, random C-peptide). General-population screening (Fr1da-style, ASK) is research-protocol-based in most regions; ADA recommends screening high-risk relatives in clinical practice and considering broader pediatric screening where infrastructure exists ADA 2024.
Teplizumab protocol: a single 14-day course of once-daily IV infusion. Dosing escalates over the first 5 days then maintains: day 1 — 65 μg/m², day 2 — 125 μg/m², day 3 — 250 μg/m², day 4 — 500 μg/m², days 5–14 — 1,030 μg/m². Each infusion ≥30 minutes; pre-medication with antipyretic/antihistamine/antiemetic recommended for cytokine-release symptoms in the first 5 days. Baseline labs required: CBC with differential, LFTs, EBV and CMV serology, current immunizations status, pregnancy test. Re-treatment with a second course has not been studied in Stage 2 patients; the FDA label permits only one course FDA 2022.
contraindications
Per the Tzield label: serious active infection, including active EBV or CMV infection or other chronic infections, is a contraindication. Lymphopenia (ALC <1,000 cells/μL pretreatment), elevated LFTs (ALT/AST >2× upper limit, or bilirubin >1.5× ULN), hypersensitivity to teplizumab, and pregnancy are contraindications or strong cautions. Cytokine release syndrome occurs in ~70% during the first 5 days (usually mild — fever, headache, GI symptoms). Lymphocyte counts fall ~60–80% during treatment and recover over 2–6 months; opportunistic infection risk is elevated transiently. Live vaccines should be deferred 8 weeks before treatment and 12 months after; inactivated vaccines should be brought up to date pre-treatment. Pregnancy: no human data; animal data suggests potential fetal harm; effective contraception required during and for 30 days after the course FDA 2022.
misconceptions
Misconception 1: "Teplizumab cures or prevents T1D." It doesn't. It delays clinical onset by a median of ~2–3 years in Stage 2 patients; on long-term follow-up, the curves continue to converge — most treated individuals eventually develop clinical T1D Sims et al. 2021. The honest framing is delay, not prevention.
Misconception 2: "Type 1 diabetes runs in families, so screening focuses there." Only ~10–15% of new T1D diagnoses have a first-degree family history. Family-based screening (TrialNet) catches the relatives, but the majority of future T1D cases live in families with no history — which is the rationale for general-population pediatric programs like Fr1da and ASK Ziegler et al. 2020.
Misconception 3: "Autoantibody positivity is a probabilistic risk." For single autoantibodies, yes — many revert. For ≥2 persistent autoantibodies in childhood, lifetime progression to clinical T1D approaches 100% Ziegler et al. 2013. The framing of "high risk" understates this — it's near-certainty over decades.
Misconception 4: "Diagnosis without symptoms is bad — better to wait." The unscreened pathway to T1D commonly ends in DKA — ~20–30% of new-onset pediatric T1D in the US presents in DKA, a life-threatening emergency with measurable long-term cognitive sequelae. Screened children present with mild hyperglycemia detected on routine monitoring; DKA at onset drops to ~3–5% Hummel et al. 2023.
audience
Direct candidates for teplizumab: Stage 2 individuals ≥8 years old. Direct candidates for screening: first- and second-degree relatives of T1D patients (TrialNet's eligibility); some research/health-system programs extend to general-population children aged 2–10 (Fr1da, ASK, regional pilots in Italy, UK). Adult-onset T1D ("LADA" presents differently and the prevention paradigm is less developed); the screening-and-delay paradigm is most actionable for children and young adults of relatives, where the long pre-clinical window gives time for both detection and treatment. Pregnancy is a hard exclusion. Patients with chronic viral infections (EBV, CMV, hepatitis) need individual evaluation.
alternatives
For Stage 2 patients: the alternative to teplizumab is "watchful waiting" — 6-monthly OGTT monitoring through TrialNet or a local endocrinologist, with prompt clinical diagnosis when Stage 3 transitions occur. Watchful waiting eliminates the cost and infusion burden of teplizumab but accepts the natural-history timeline (median ~2 years to clinical T1D from Stage 2). Other immunomodulators studied in T1D prevention or new-onset preservation — abatacept, low-dose ATG, rituximab, golimumab, verapamil, oral insulin (DPT-1, TN-07), nasal insulin (INIT, DIPP-IT) — have shown smaller or null effects in prevention; none is FDA-approved for delay. Verapamil has small RCTs showing C-peptide preservation in new-onset T1D (Forlenza et al. 2023, others) but no prevention trials at Stage 2 yet.
failure-modes
Common failure modes: (1) Screening declined because the family doesn't perceive the benefit — when "knowing 5 years early" is framed as anxiety-inducing rather than DKA-preventing, uptake falls. (2) Screen-positive but lost to follow-up — the median lag between Stage 2 diagnosis and clinical T1D is long enough that families drift; failure to maintain 6-monthly monitoring forfeits both the teplizumab window and the DKA-prevention benefit. (3) Teplizumab given outside the optimal window — too early (Stage 1, low risk over short horizon) or too late (already Stage 3, FDA label not approved, PROTECT supports use but reimbursement is harder). (4) Insurance denial or prior-authorization delays during the narrow Stage-2 window; ~25% denial rate reported in early post-approval real-world data, often overturned on appeal. (5) Lymphopenia-driven infection in the 2–6 months post-treatment; missed monitoring causes preventable hospitalizations. (6) Re-treatment expectation — patients and families expecting a second course after onset is delayed are disappointed; only one course is FDA-approved.
practicalities
Cost: list price $193,900 USD for the 14-day course (Provention Bio / Sanofi). Major US payers (Medicare, most private insurers) cover teplizumab when Stage 2 criteria are met, with prior authorization; out-of-pocket varies from $0 (Medicaid, some commercial plans) to several thousand dollars (high-deductible plans). Provention Bio's patient assistance program covers some uninsured/underinsured. Outside the US, NICE has not yet recommended teplizumab (under review as of 2024); Germany and some EU countries have early-access pathways. Infusion logistics: a specialty infusion center (often hospital-based) for 14 consecutive weekdays, ~1.5–2.5 hours per visit (including pre-meds, infusion, post-observation); families typically arrange school or work accommodations for the two-week course. Screening: TrialNet screening is free and can be done at home (capillary kit mailed) or at participating sites; turnaround 4–6 weeks. ASK and Fr1da screening is free within the research catchment ICER 2023 McQueen et al. 2020.
history
Anti-CD3 antibodies entered T1D research in the early 2000s. Muromonab-CD3 (OKT3) was the first-generation antibody used in transplant rejection (1986); cytokine release made it unusable in chronic autoimmune disease. Fc-modified versions — teplizumab (hOKT3γ1[Ala-Ala]) and otelixizumab — reduced cytokine release and entered T1D trials in the 2000s. Early trials in new-onset T1D showed C-peptide preservation (Herold 2002, Keymeulen 2005, Herold 2013); a phase-3 prevention trial in Stage-2 relatives launched as TN-10 in 2011 through TrialNet. After publication in 2019 and extended follow-up in 2021, Provention Bio filed for FDA approval; an initial Complete Response Letter (2021) cited manufacturing/PK comparability issues that were resolved, and approval came in November 2022. Sanofi acquired Provention Bio in 2023, signaling commercial commitment. Screening infrastructure predated the drug: DPT-1 (1994) → TrialNet Pathway to Prevention (2004) had been screening relatives for two decades when teplizumab arrived Herold et al. 2013 FDA 2022.
stakes
Unmonitored progression to Stage 3 T1D commonly ends in DKA — vomiting, abdominal pain, Kussmaul breathing, altered consciousness, ICU admission, ~0.15–0.30% mortality. ~20–30% of US pediatric T1D presents this way; in lower-income regions, higher. Long-term complications scale with total hyperglycemia exposure: starting T1D 2–3 years later means 2–3 fewer years of microvascular damage onset, all else equal. DCCT and EDIC follow-up show every year of poor early control compounds retinopathy, nephropathy, and cardiovascular risk decades later. For the family, the unscreened scenario is the 3-AM ER trip with a confused, dehydrated child — followed by a sudden, unprepared transition to lifelong insulin management. Knowing earlier doesn't change the diagnosis arriving; it changes how it arrives.
payoff
For the Stage-2 family who screens and treats: ~2–3 additional median years of normal pancreatic function — for a child, the difference between starting middle school as a normal-glucose 11-year-old versus a newly-diagnosed T1D 9-year-old. Insulin-free years are not symbolic — every additional year before insulin onset is one less year of finger-sticks, pump-site rotations, hypoglycemia management, and 24/7 carb-counting vigilance. Even when T1D eventually arrives, DKA at presentation is uncommon when monitoring catches the transition early; the diagnosis arrives in an endocrinology clinic, not an emergency room. For families who screen and learn they're negative: the gradual fade of background worry over a younger sibling or a child whose cousin has T1D. For those who screen positive but don't (yet) treat: structured monitoring replaces vague anxiety with a known trajectory.
out-of-scope
Adjacent topics this entry doesn't cover: continuous glucose monitoring (CGM) and closed-loop insulin systems, which are the standard-of-care frame for established T1D; β-cell replacement therapies (islet transplantation, stem-cell-derived β-cells like VX-880); type 2 diabetes prevention (metformin, lifestyle — different pathophysiology); the genetic-risk scores (T1D-GRS2) sometimes used to enrich screening; primary prevention via dietary or microbiome interventions in infancy (TEDDY-led research, no FDA-approved intervention).
The credibility range
Optimist case
Teplizumab is the first disease-modifying therapy in the 100-year history of insulin-era T1D. The TN-10 trial used a rigorous trial design (randomized, double-blind, placebo-controlled), in a precisely-defined population (Stage 2 relatives), with a clinically meaningful endpoint (time to clinical T1D), and showed a hazard ratio of 0.41 with a 32.5-month median delay on extended follow-up. The mechanism is biologically coherent: pause autoreactive T-cell killing of β-cells, preserve β-cell mass, extend the pre-clinical window. PROTECT independently confirms β-cell preservation at new-onset. Screening at Stage 1/2 reduces DKA at clinical diagnosis from 20–30% to ~3–5%, an effect size on par with the largest preventive interventions in pediatrics. The combined screening-plus-drug pathway is one of the cleanest "find it early, change the trajectory" stories in modern medicine. The cost is high but a single course delaying multi-year complications is plausibly cost-effective; coverage is broadening. Long-term, repeat or combination dosing may extend the delay further. This is the prototype for autoimmune-disease prevention — RA, MS, lupus all watching.
Skeptic case
TN-10 randomized only 76 patients. The confidence interval on the hazard ratio is wide (0.22–0.78). The eventual Kaplan–Meier curves converge: most teplizumab recipients still develop clinical T1D. We've delayed disease, not prevented it. The 24- to 32-month delay is reported as a median; some patients show no delay, and we can't predict who. $193,900 for a 2-to-3-year delay, with eventual T1D anyway, is a hard cost-effectiveness sell — ICER's 2023 analysis found teplizumab exceeds standard willingness-to-pay thresholds under most assumptions ICER 2023. Lymphopenia and infection risk are real, even if usually transient. Screening identifies children who are statistically destined for T1D but in the meantime live with a label and family anxiety — TEDDY and DAISY data show measurable psychological impact, especially initially Johnson et al. 2011. General-population screening at the scale Fr1da achieves is logistically expensive and may not be feasible outside research-funded settings. We do not yet have an off-ramp: positive screen → 6-monthly monitoring → eventual diagnosis is still the modal trajectory, with or without teplizumab. The bigger question — whether to combine teplizumab with verapamil, anti-thymocyte globulin, or a future therapy — remains unanswered.
Author's call
Both screening and teplizumab are real, evidence-based interventions with meaningful (not dominant) effects on the T1D trajectory. For first-degree relatives of a T1D patient, screening through TrialNet is a high-value action: it's free, low-burden, and the downside (knowing earlier) is genuinely smaller than the upside (DKA avoidance, treatment window). The teplizumab decision is harder: a 2–3 year median delay matters, especially during childhood (compressing the developmental years spent with T1D burden), but it's neither cure nor prevention and the cost is substantial. For Stage 2 children where insurance covers it, the case is strong; for adults late in the Stage-2 window, the case weakens (less remaining pre-clinical time to delay). The screening case is broader and more confident than the drug case. The article should lead with screening's value (especially DKA avoidance) and frame teplizumab as the high-stakes downstream decision that screening makes possible — honest about the delay-not-cure framing.
Stakeholder + incentive map
Pushing the screening + drug pathway: JDRF (now Breakthrough T1D) — decades-long funder of TrialNet, TEDDY, prevention research, and Provention Bio's early development; has both mission and reputational stake in disease-modifying T1D therapy. Sanofi (acquired Provention Bio 2023) — commercial stake in teplizumab uptake; markets Tzield. TrialNet (NIH/NIDDK + JDRF-funded consortium) — academic infrastructure built around the screening-and-prevention paradigm. Pediatric endocrinology societies (ISPAD, Pediatric Endocrine Society) — clinical advocacy. ADA — incorporated the staging framework and screening recommendations into Standards of Care 2024.
Counter-incentives / friction: Insurance payers — initial prior-authorization barriers; ICER's negative cost-effectiveness assessment provides ammunition for restrictive coverage. Pediatric primary care — wary of identifying asymptomatic disease without an unambiguous treatment, and of medicalizing healthy children. Some bioethicists — concerns about screening minors for incurable progressive disease, parental anxiety, surveillance burden. Skeptical endocrinologists — point to converging Kaplan–Meier curves and ask whether 2–3 years is worth $194,000 plus infusion risk.
Family decision drivers: Parents with one child already diagnosed often pursue screening for siblings aggressively (the "spare the next one" motivation); families with no T1D history have to opt into general-population pilots, with uptake driven by school/pediatrician referral and trust in the screening organization. Cultural and educational variables drive uptake more than risk: Fr1da achieved >90% screen-return rates through pediatric-office partnership.
Population variability
Age of seroconversion: Children who seroconvert before age 3 progress fastest; those who seroconvert in adolescence or adulthood progress more slowly. Stage 2 at age 8 has a different median time-to-clinical than Stage 2 at age 25 — the trial data are skewed pediatric.
Number and identity of autoantibodies: IA-2 positivity, especially combined with mIAA, predicts faster progression than GAD65 alone. Three or four autoantibodies progress faster than two Ziegler et al. 2013.
HLA genotype: HLA-DR3/DR4-DQ8 heterozygotes have the highest baseline T1D risk; T1D-Genetic Risk Score (T1D-GRS2) can stratify screening pre-test probability but isn't routinely required for TrialNet enrollment.
Race / ethnicity: Most published trial data (TN-10, PROTECT) skew white and high-income — predictable from the TrialNet recruitment base. Generalizability to Hispanic, Black, Asian, and lower-income US populations is plausible (mechanism is shared) but undertested. Fr1da is similarly Bavarian/European.
Sex: No strong sex-specific signal in teplizumab response. Pregnancy excludes the drug.
Treatment response heterogeneity: Within TN-10, baseline metabolic and immune features (HLA-DR3 positivity, baseline C-peptide trajectory) predicted larger response. Some patients show 5+ year delays; others show none. Predictive markers for teplizumab response are an active research area.
Knowledge gaps
Whether a second teplizumab course (re-treatment) extends the delay further — not yet studied in Stage 2; some evidence of feasibility in new-onset but no FDA pathway.
Whether combining teplizumab with other immunomodulators (low-dose ATG, verapamil, GLP-1 agonists, JAK inhibitors) can extend the delay or move from delay toward prevention. Active trial pipeline.
Long-term efficacy beyond ~7 years post-treatment — TN-10 cohort follow-up continues but the convergence trajectory of Kaplan–Meier curves at very long timepoints is uncertain.
Cost-effectiveness at willingness-to-pay thresholds reasonable for US payers — sensitive to assumptions about delay-duration extrapolation, complication-cost discounting, and quality-of-life utilities during the delay vs post-onset.
Optimal timing — is there a "sweet spot" within Stage 2 where teplizumab is most effective? Sub-staging of Stage 2 by metabolic trajectory (OGTT curve shape, HbA1c trend) is being studied but not yet operationalized.
Whether universal pediatric screening (general-population, Fr1da-scale) is cost-effective at population scale and politically/logistically deliverable in mixed payer systems like the US.
Adult-onset T1D and LADA — screening and treatment paradigms are immature; teplizumab not approved or tested in LADA.
Long-term psychological and family-system effects of pediatric autoantibody-positive status across 5–15 year horizons — limited data beyond the first few years post-screen Hummel et al. 2017.
Scope coupling. The entry treats screening and teplizumab as a single substance because they only make sense together — the drug requires the screen, and the screen is what makes the drug actionable. Brief named both pieces plus time-to-diagnosis, screening uptake, and family decision-making; all four are covered end-to-end (uptake in failure-modes and audience, family decision-making in payoff and stakes). Nothing silently dropped.
Action = test, not decide. The treatment decision is genuinely a decide (prescription-only, clinician-led, high-stakes tradeoff), but the entry-point reader-action is screening. Treatment is downstream of test; framing the entry around test matches where readers actually enter the pathway. Cadence once covers the initial screening decision; the every-year re-screen for negative under-18s and 6-monthly metabolic monitoring for positives are downstream cadences, not the entry's headline action.
Longevity scored 4, not 5. TN-10 plus extended follow-up shows a real 2-to-3-year median delay with DKA-avoidance amplifying long-term complication-risk reduction — large effect, well-evidenced. Held below 5 because the Kaplan–Meier curves converge on long follow-up (delay, not prevention) and the trial population is small (n=76). A 5 anchor wants a multi-trial dominant longevity effect; teplizumab earns a strong 4.
Cost burden scored 4, not 5. Insured US cases are typically covered with prior auth; out-of-pocket varies $0 to several thousand. Cash exposure of $194K would be a 5, but for the modal insured reader the effective cost is major-but-manageable. A 4 is honest about both the sticker shock and the typical real exposure.
Evidence scored 4, not 5. Single pivotal RCT plus extended follow-up plus a confirmatory phase-3 in new-onset is strong but not multi-trial Cochrane-level prevention evidence. Holding below 5 keeps the line credible.
Mood scored 1, not 0 or 2. The literature shows both directions — initial parental distress that adapts, plus relief from a known trajectory in T1D-aware families. Net small positive for the modal family with a T1D relative; smaller or neutral for general-population screens. Kept conservative.
Contraindication tokens. Only pregnancy applied from the closed vocabulary. Lymphopenia, EBV/CMV reactivation, abnormal LFTs, and prior hypersensitivity are baseline-visit screening checks at the infusion center, not population-level lifelong tokens — adding them would mis-signal that anyone with a past CMV infection is permanently disqualified. The article body covers the full safety screen in contraindications.
Audience left unrestricted. Pediatric candidates are the highest-yield population, but parents of all ages make the decision, and adult relatives of T1D patients are also eligible for screening. Restricting audience.ages would falsely narrow reach.
History omitted as a standalone section. The "first-ever disease-modifying T1D drug" framing carries narrative weight, but it landed naturally in evidence and practicalities; a dedicated history section would have padded. Kept in the research dossier.
PROTECT (new-onset) treated as supporting, not central. The FDA label is Stage 2 delay; PROTECT confirms the mechanism in new-onset but isn't an approved indication. Citing it strengthens the evidence base without confusing readers about what teplizumab is approved to do.
Separate-entry candidates. Type 1 diabetes itself (the disease) — currently no entry; DKA recognition and emergency response — warrants its own respond-action entry; the JDRF/ADA staging framework could be its own entry but probably belongs nested inside a T1D parent entry. Continuous glucose monitoring and closed-loop insulin systems are standalone candidates. Islet transplantation and stem-cell beta-cell therapies (VX-880, etc.) are early but worth a future entry.
Future-link candidates. Once the above exist: link to the T1D entry from the dek, link to CGM/closed-loop from out-of-scope, link to DKA-recognition from stakes, and link to islet/stem-cell therapies from out-of-scope. T1D-GRS2 (genetic risk scoring) flagged in out-of-scope for an eventual genomics-screening entry.
Rating difficulty noted. Health-short-term was the hardest call — the drug itself produces transient negatives (cytokine release, lymphopenia) within weeks, while the felt short-term wellness benefit is mostly the absence of DKA, which is hard to score on a "felt within weeks" axis. Landed on 2 because the DKA-avoidance benefit is real and concrete even if it operates through a non-event.
Teplizumab and T1D Screening
TN-10 RCT (Herold et al. 2019) showed a median 24-month delay in time to clinical T1D from a single 14-day teplizumab course in Stage 2 relatives; extended follow-up (Sims et al. 2021) widened the median delay to ~32.5 months with 50% vs 22% remaining diabetes-free. Years of normal pancreatic function and reduced DKA at onset translate to less cumulative hyperglycemia and lower long-term microvascular complication risk.
Screening is a single blood draw (capillary or venous) with mailed at-home kits available through TrialNet — trivial. Treatment requires 14 consecutive weekday IV infusions (~1.5–2.5 hours each) at a specialty infusion center, plus 6-monthly metabolic monitoring (OGTT, HbA1c) afterward — a defined burden over weeks, not a daily ongoing one.
Single pivotal RCT (TN-10, n=76, Herold et al. 2019) with consistent extended follow-up (Sims et al. 2021); independent confirmation of β-cell preservation in newly-diagnosed T1D (PROTECT phase 3, Ramos et al. 2023); FDA-approved 2022; ADA Standards of Care 2024 endorse the staging-and-screening framework. Sample size and population diversity limit it below a multi-trial 5.
Through structured monitoring after a positive screen, DKA at clinical T1D diagnosis falls from ~20–30% to ~3–5% (Hummel et al. 2023, Fr1da cohort) — the felt difference between a routine endocrinology visit and an ICU admission. Drug-side short-term effect modest: transient cytokine-release symptoms and lymphopenia balance against earlier metabolic stability.
Screening through TrialNet is free; the teplizumab course carries a US list price of $193,900 (ICER 2023). Most US insurers cover with prior authorization for Stage 2 criteria, but out-of-pocket varies from $0 (Medicaid, low-deductible plans) to several thousand on high-deductible plans, and uninsured cash exposure is prohibitive.
Mixed direction: initial parental anxiety after a positive autoantibody result is real (Johnson et al. 2011 TEDDY, Hummel et al. 2017 Fr1da), but adapts within months; structured monitoring replaces vague background worry common in T1D-relative families with a known trajectory. Net small positive in families with prior T1D awareness; smaller or neutral effect in general-population screen-positives.